


**Kopran**

**KOPRAN LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31st DECEMBER, 2014**

Part I Particulars	Quarter ended			Nine Months ended		(₹. in lakhs)
	31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	Year ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sales / Income from Operations	6868	7749	7628	21313	21292	29417
Other Operating Income	131	192	173	465	570	779
<b>Total Income from operations</b>	<b>6999</b>	<b>7941</b>	<b>7801</b>	<b>21778</b>	<b>21862</b>	<b>30196</b>
Expenditure						
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	223	(630)	204	(533)	(423)	(636)
Cost of Materials Consumed	4163	5696	4563	14391	13400	18,750
Purchase of Stock- in - trade	16	48	219	107	361	578
Employee Benefits Expenses	751	673	611	2016	1750	2,296
Depreciation	330	323	315	968	926	1,246
Other Expenses	1140	1401	1240	3627	3580	4,945
<b>Total Expenses</b>	<b>6623</b>	<b>7511</b>	<b>7152</b>	<b>20576</b>	<b>19594</b>	<b>27,179</b>
<b>Profit (Loss) from operations before other income, interest and exceptional items</b>	<b>376</b>	<b>430</b>	<b>649</b>	<b>1,202</b>	<b>2,268</b>	<b>3,017</b>
Other Income	12	45	18	66	22	89
Foreign Exchange Gain/ (Loss)	88	138	1	417	(158)	44
<b>Profit (Loss) before interest and exceptional items</b>	<b>476</b>	<b>613</b>	<b>668</b>	<b>1,685</b>	<b>2,132</b>	<b>3,150</b>
Finance Cost	324	304	361	921	1,043	1,446
<b>Profit (Loss) before exceptional items</b>	<b>152</b>	<b>309</b>	<b>307</b>	<b>764</b>	<b>1,089</b>	<b>1,704</b>
Exceptional items	-	-	-	-	-	-
<b>Profit ( Loss ) before tax</b>	<b>152</b>	<b>309</b>	<b>307</b>	<b>764</b>	<b>1,089</b>	<b>1,704</b>
Less :Tax expenses	-	-	-	-	-	-
<b>Net Profit for the period</b>	<b>152</b>	<b>309</b>	<b>307</b>	<b>764</b>	<b>1,089</b>	<b>1,704</b>
Paid up equity share Capital (Face value Rs 10/-)	4,110	3,905	3,905	4,110	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	9,752
<b>Earning Per Share ( EPS ) before and after Exceptional Item</b>						
a) Basic	0.38	0.79	0.79	1.94	2.79	4.36
b) Diluted	0.38	0.79	0.79	1.94	2.79	4.36
<b>Part II</b>						
<b>(A) PARTICULARS OF SHAREHOLDING</b>						
Public shareholding						
Number of shares	23753463	23753463	23753463	23753463	23753463	23753463
Percentage of shareholding	57.80%	60.83%	60.83%	57.80%	60.83%	60.83%
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	3352500	3352500	3352500	3352500	3352500	3352500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.33%	21.92%	21.92%	19.33%	21.92%	21.92%
Percentage of shares (as a % of the total share capital of the company)	8.16%	8.59%	8.59%	8.16%	8.59%	8.59%
b) Non - encumbered						
Number of shares	13993513	11943513	11943513	13993513	11943513	11943513
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	80.67%	78.08%	78.08%	80.67%	78.08%	78.08%
Percentage of shares (as a % of the total share capital of the company)	34.05%	30.58%	30.58%	34.05%	30.58%	30.58%
<b>(B) INVESTOR COMPLAINTS</b>				3 Months ended 31/12/2014		
Pending at the beginning of the quarter						-
Received during the quarter						11
Disposed off during the quarter						11
Remaining unresolved at the end of the quarter						-





# Kopran

Reporting of Segment wise Revenue, Result and Capital Employed						
Particulars	Quarter ended			Nine Months ended		Year ended
	31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014
<b>1. Segment Revenue</b>	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Pharamaceutical	7,144	8,064	8,019	22,189	22,337	30,880
(b) Consumer Care Division	60	65	67	186	185	246
<b>Total</b>	<b>7,204</b>	<b>8,129</b>	<b>8,086</b>	<b>22,375</b>	<b>22,522</b>	<b>31,126</b>
Less : Inter-Segment Revenue	-	-	-	-	-	-
Less : Excise Duty	205	188	285	597	660	930
<b>Net Sales/ Income from Operation</b>	<b>6,999</b>	<b>7,941</b>	<b>7,801</b>	<b>21,778</b>	<b>21,862</b>	<b>30,196</b>
<b>2. Segment Results</b>						
(a) Pharamaceutical	526	682	742	1,872	2,308	3,417
(b) Consumer Care Division	(50)	(69)	(74)	(187)	(176)	(267)
<b>Total</b>	<b>476</b>	<b>613</b>	<b>668</b>	<b>1,685</b>	<b>2,132</b>	<b>3,150</b>
Less: Finance Cost	324	304	361	921	1,042	1,446
<b>Total Profit Before Tax</b>	<b>152</b>	<b>309</b>	<b>307</b>	<b>764</b>	<b>1,090</b>	<b>1,704</b>
<b>3. Capital Employed</b>						
(a) Pharamaceutical	21,490	21,270	21,014	21,490	21,014	21,556
(b) Consumer Care Division	652	573	258	652	258	397
(c) Others (Unallocated)	5,407	5,418	5,425	5,407	5,425	5,416
<b>Total</b>	<b>27,549</b>	<b>27,261</b>	<b>26,697</b>	<b>27,549</b>	<b>26,697</b>	<b>27,369</b>

**Notes:-**

(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 13th February, 2015 Limited review has been carried out by statutory auditor of the company.

(2) The company is in process of technically evaluating useful lives of its fixed assets and componentization thereof vis-à-vis the useful lives stated under Schedule II of the Companies Act, 2013. Pending such evaluation, the company has provided depreciation for the quarter by applying the rates that were applicable for the previous financial year. Its impact is unascertainable at this stage and adjustment shall be carried out in subsequent quarter after finalisation of technical evaluation/componentization.

(3) During the quarter the company has issued and allotted 20,50,000 Equity Shares of Rs.10/- each at premium of Rs.56/- per Equity Share and 21,50,000 Convertible Warrants @ Rs.66/- per warrant on preferential basis to M/s. Oricon Properties Ltd. convertible into equal number of equity shares within 18 months from 26.11.2014.

**(4) Auditors observation:**

a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 31-12-2014 amounting to Rs. 5220.97 Lacs,(as at 31-12-2013 Rs 5238.42 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.

(5) Figures for the previous accounting period have been regrouped wherever necessary.

KOPRAN LIMITED

Surendra Somani  
Executive Vice Chairman

Place : Mumbai  
Date: 13-02-2015

